5 Steps to Building Author Rank for your Dermatology Practice
Google is constantly trying to improve search quality for its users. SEO professionals with robust content strategies in place stand to benefit from this the most. To beat spammers, the search engine giant has been focusing on establishing an ecosystem of "content identity;" the aim is to have a verified source for each piece of content that makes it to search queries. Best Practices for Building Authorship Products and services such as Google+ and Google Authorship are among its long…
  • Latest Ideas

  • Choosing the Right Social Platform for your Medical Mobile Marketing
    With the sharp growth of the mobile social ecosystem, it has become important for medical marketers to be highly strategic about their choices of social platforms with regard to mobile marketing. The target readers keep switching between Facebook, Twitter, Instagram, Pinterest and other networks, and the content is digested differently in each network. For instance, a predominantly visual network such as Pinterest gets more engagement from female audience, while Twitter or Facebook are much more diverse in their user base.…
  • Latest Think Like an Entrepreneur Articles

  • July 2014

    Building a compelling Brand for your Dental or Healthcare Practice
  • Latest Videos

  • Psoriasis and bone mineral density: Implications for long-term patients
    Psoriasis is a chronic inflammatory disease associated with several comorbidities. Osteoporosis is defined as a reduction in bone mineral density with impaired bone microarchitecture. Several mechanisms may be implicated as a possible cause for the association between psoriasis and osteoporosis, such as systemic inflammation, anti-psoriatic drug intake and joint dysfunction for psoriatic arthritis (PsA). The aim of the present study was to assess bone mineral density (BMD) in patients with psoriasis, correlating the prevalence of osteopenia/osteoporosis with Psoriasis Area and…
    Nivolumab: A review of its use in patients with malignant melanoma
    Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous nivolumab to be used in the treatment of advanced malignancies such as melanoma was initially demonstrated in phase I dose-ranging trials. Subsequently, in a noncomparative, open-label, phase II trial, almost one-quarter of Japanese patients with previously treated…
  • Latest Clinical Articles